Status:

COMPLETED

A Research Study to Compare a New Weekly Insulin, Insulin Icodec, and an Available Daily Insulin, Insulin Degludec, Both in Combination With Mealtime Insulin in People With Type 1 Diabetes (ONWARDS 6)

Lead Sponsor:

Novo Nordisk A/S

Conditions:

Diabetes Mellitus, Type 1

Eligibility:

All Genders

18+ years

Phase:

PHASE3

Brief Summary

This study compares insulin icodec (a new insulin) to insulin degludec (an insulin already available on the market) in people with type 1 diabetes. The study will look at how well insulin icodec take...

Eligibility Criteria

Inclusion

  • Male or female aged greater than or equal to 18 years at the time of signing informed consent.
  • Diagnosed with type 1 diabetes mellitus greater than or equal to 1 year prior to the day of screening.
  • Treated with multiple daily insulin injections (basal and bolus insulin analogue regimes) greater than or equal to 1 year prior to the day of screening.
  • HbA1c below10% at screening visit based on analysis from central laboratory.

Exclusion

  • Myocardial infarction, stroke, hospitalization for unstable angina pectoris or transient ischaemic attack within 180 days prior to the day of screening.
  • Chronic heart failure classified as New York Heart Association (NYHA) Class IV at screening.
  • Anticipated initiation or change in concomitant medications (for more than 14 consecutive days) known to affect weight or glucose metabolism (e.g. treatment with orlistat, thyroid hormones, or corticosteroids).
  • Uncontrolled and potentially unstable diabetic retinopathy or maculopathy. Verified by a fundus examination performed within the past 90 days prior to screening or in the period between screening and randomisation. Pharmacological pupil-dilation is a requirement unless using a digital fundus photography camera specified for non-dilated examination.

Key Trial Info

Start Date :

April 30 2021

Trial Type :

INTERVENTIONAL

Allocation :

ACTUAL

End Date :

December 2 2022

Estimated Enrollment :

582 Patients enrolled

Trial Details

Trial ID

NCT04848480

Start Date

April 30 2021

End Date

December 2 2022

Last Update

December 4 2025

Active Locations (130)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 33 (130 locations)

1

John Muir Physicians Network

Concord, California, United States, 94520

2

Headlands Research California, LLC

Escondido, California, United States, 92025

3

Valley Research

Fresno, California, United States, 93720

4

Scripps Whittier Diabetes Inst

La Jolla, California, United States, 92037